Skip to content

Inspection Record

Genlbet Biopbarmaceuticals SA — FDA 483 Findings

US FDAInspected 2023-01-31Published 2026-10-20 3 findingsContamination controlEquipment and facility

View the regulator's official source The source document is always the basis for judgement.

Findings

1Contamination control

Decontamination is incomplete or not adequately demonstrated to ensure prevention of cross-contamination.

2Equipment and facility

Equipment cleaning processes are inadequate.

3Equipment and facility

Written procedures for decontamination, cleaning, and maintenance of equipment are deficient regarding sufficient details to protect equipment from contamination prior to use.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Genlbet Biopbarmaceuticals SA company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.